Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.
about
Modern approaches to HLA-haploidentical blood or marrow transplantationPost-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantationTransplantation tolerance: from theory to clinic.Induction of donor-specific transplantation tolerance to skin and cardiac allografts using mixed chimerism in (A + B-->A) in ratsXenobiotics, chimerism and the induction of tolerance following organ transplantation.Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamideNonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamideMurine anti-third-party central-memory CD8(+) T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells.Hematopoietic chimerism and transplantation tolerance: a role for regulatory T cells.Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation.Cross-species transplantation tolerance: rat bone marrow-derived cells can contribute to the ligand for negative selection of mouse T cell receptor V beta in chimeras tolerant to xenogeneic antigens (mouse + rat----mouse).HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide.Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens.Tolerization of anti-Galalpha1-3Gal natural antibody-forming B cells by induction of mixed chimerism.Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance.A strategy for organ allografts without using immunosuppressants or irradiation.Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantationPreclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4.Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy.Bidirectional immune tolerance in nonmyeloablative MHC-mismatched BMT for murine β-thalassemia.Xenograft tolerance.Induction of Pancreatic Islet Graft Acceptance: The Role of Antigen Presenting CellsMechanisms of Tolerance Induction by Hematopoietic Chimerism: The Immune Perspective.Apoptotic signaling through Fas and TNF receptors ameliorates GVHD in mobilized peripheral blood grafts.Cyclophosphamide-induced tolerance in kidney transplantation avoids long-term immunosuppressive therapy.
P2860
Q26797506-797F7A7B-88E6-4574-8C82-DCCA72FC47E6Q26852474-F433916C-F7DF-41A0-81C1-0D7249A42B25Q34082059-07F0B47C-937D-487B-8C7B-87C0201C51A6Q34291866-5866DA15-437F-4A8B-80A4-E4AC04C1482EQ34357964-45597263-A7E5-41FD-B0C7-652B38703A9FQ35478934-3905DED8-9A33-4144-B213-FA74E53A929AQ35505839-64C8AABF-343E-47B7-91DE-90727341FB03Q35743914-754844F3-C84C-47A6-888B-527B1C019FDAQ35928393-3816375F-6AA9-4BD3-8CAB-82709BA99FD7Q36130498-A87702AD-C9CC-4896-9761-89F79A7D8E1EQ36230864-3E7B2BC8-6D97-4306-B96D-7530E0F35AB5Q36253363-E4A584A4-CBBD-4238-87E4-C3043AFC14D6Q36350179-FF3B36EF-9C40-43C0-B93C-7356F81AE91BQ36400683-60EE8E56-11EB-4B07-8063-C100491E96FBQ36401145-846479B8-7F47-413F-A8A9-EB44B8243E47Q36500674-32BADDEE-6AE7-44DD-8456-65BAFD05E7C2Q36724916-61E84491-F349-4F77-BFDA-B62785F77E68Q36833808-B5B37376-4891-456E-A244-1947B30A60C0Q37035815-D3AF0579-BA82-40D5-9AE3-9EAE5C4E3074Q37382702-44012751-0BD9-4F74-BA40-9DCBA456765BQ37603816-F174D3DE-62F3-4486-B307-A87854F9BED9Q38870274-700988C3-0451-46C8-B74A-ECE010B91A22Q40600287-66241517-8A99-4A54-84E7-6773D9D70405Q41770384-EE0C57D1-F12D-4623-BDBD-F2AD603A1CFAQ42247792-8B2B904F-BD8B-4B03-9AE1-0267E322F093Q43976705-67904DFF-5EBF-4018-A4BC-A57C4D725DA7Q50145136-6754CE3B-8756-4421-ABCF-4729776FC7B1
P2860
Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Long-lasting skin allograft to ...... method using cyclophosphamide.
@ast
Long-lasting skin allograft to ...... method using cyclophosphamide.
@en
type
label
Long-lasting skin allograft to ...... method using cyclophosphamide.
@ast
Long-lasting skin allograft to ...... method using cyclophosphamide.
@en
prefLabel
Long-lasting skin allograft to ...... method using cyclophosphamide.
@ast
Long-lasting skin allograft to ...... method using cyclophosphamide.
@en
P2860
P356
P1476
Long-lasting skin allograft to ...... method using cyclophosphamide.
@en
P2093
P2860
P304
P356
10.1084/JEM.169.1.213
P407
P577
1989-01-01T00:00:00Z